Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 ,inter alia, to consider and approve This is to inform you ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Oxygenta Pharmaceutical Ltd has informed BSE that its Board of Directors will meet on Friday, May 30, 2025, to consider and approve the audited financial results for the fourth quarter and full financial year ended March 31, 2025. The intimation is being made under Regulation 29 of SEBI (LODR) Regulations, 2015. The trading window for designated persons and their immediate relatives will remain closed until June 01, 2025, which is 48 hours after the board meeting. Dolly Lakhichand Mandhan, Company Secretary & Compliance Officer, has signed the filing.
This is a routine regulatory intimation with no material impact on the stock. Investors should wait for the actual Q4 and FY25 results on May 30, 2025, to assess the company's financial performance.